<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Coronary artery bypass surgery: Perioperative medical management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Coronary artery bypass surgery: Perioperative medical management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Coronary artery bypass surgery: Perioperative medical management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sary Aranki, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Simon Maltais, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hadi D Toeg, MD, MSc, MPH, FRCSC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gabriel S Aldea, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Edward Verrier, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Guy S Reeder, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The treatment of coronary heart disease (CHD) has evolved significantly over the past several years due in part to improvement in both surgical and percutaneous revascularization techniques. The majority of patients with chronic stable angina are still treated with medical therapy; however, revascularization with either coronary artery bypass graft surgery (CABG) or percutaneous coronary intervention should be considered in several subgroups. (See  <a class="medical medical_review" href="/z/d/html/1557.html" rel="external">"Chronic coronary syndrome: Indications for revascularization"</a>.)</p><p>The medical therapies that can minimize the short-term, particularly perioperative complications that can occur following conventional CABG (using cardiopulmonary bypass) will be reviewed here. A general discussion of the early complications of CABG is presented separately. (See  <a class="medical medical_review" href="/z/d/html/1585.html" rel="external">"Early noncardiac complications of coronary artery bypass graft surgery"</a>.)</p><p class="headingAnchor" id="H210079815"><span class="h1">SECONDARY PREVENTION MEDICATIONS</span></p><p class="headingAnchor" id="H2"><span class="h2">Aspirin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> should be administered to all patients without a contraindication who have cardiovascular disease. (See  <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">"Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"</a>.)</p><p>With respect to efficacy in patients undergoing coronary artery bypass graft surgery (CABG), a systematic review from the Antiplatelet Trialists' Collaboration concluded that antiplatelet therapy, particularly if given early, was associated with improved graft patency at an average of one year after surgery (pooled odds reduction for graft closure of 44 percent) [<a href="#rid1">1</a>]. This benefit was similar with low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (75 to 325 mg/day) as with higher and more gastrotoxic doses. Antacids and proton pump inhibitors are commonly given in the perioperative period to further attenuate this risk.</p><p class="headingAnchor" id="H3"><span class="h3">Preoperative aspirin</span><span class="headingEndMark"> — </span>All patients with cardiovascular disease (CVD) should receive lifelong <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> to prevent ischemic cardiovascular events. Thus, most patients referred for CABG take aspirin daily and we continue aspirin until surgery. For patients with a new diagnosis of CVD (and not taking aspirin) and who need CABG, the decision to start aspirin preoperatively should be individualized, taking into account the duration of the delay to surgery (ie, risk of an ischemic event in the interval between diagnosis and CABG), the bleeding risk at the time of surgery, and potential problems associated with starting a new medication shortly before surgery. If the delay is more than five days, we start aspirin in most cases. If the delay is less than five days, most of our experts start aspirin in patients not at high bleeding risk. </p><p>In general, the decision to start or to continue <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> prior to CABG needs to balance the risks of excess bleeding with potential benefits such as increased graft patency or survival or a lower rate of perioperative ischemic events [<a href="#rid2">2,3</a>]. The following studies attempted to clarify the role of aspirin in patients who will be having CABG within four or five days.</p><p>The ATACAS trial randomly assigned 2100 stable CABG patients to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (100 mg) or placebo administered one to two hours before surgery [<a href="#rid4">4</a>]. Patients enrolled in the trial were not taking aspirin prior to enrollment or stopped taking aspirin for at least five days before CABG. There was no difference in the rate of the primary outcome (death, nonfatal myocardial infarction, stroke, pulmonary embolism, renal failure, or bowel infarction) within 30 days (19.3 versus 20.4 percent; relative risk 0.94, 95% CI 0.80-1.12). There were similar rates of major hemorrhage leading to reoperation (1.8 versus 2.1 percent), cardiac tamponade (1.1 versus 0.4 percent), and mortality (1.3 versus 0.9 percent). At one year, the rates of the combined outcome of death or severe disability (the primary outcome) were similar between groups, as were the rates of death, stroke, or myocardial infarction [<a href="#rid5">5</a>]. </p><p>Older (than ATACAS) studies had come to differing conclusions regarding the net benefit and harm of preoperative <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>: </p><p class="bulletIndent1"><span class="glyph">●</span>Randomized trials published in 1990 and 1991 found that preoperative <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy increased the need for reoperation for postoperative bleeding (6.6 versus 1.7 percent and 6.3 versus 2.4 percent in two trials) [<a href="#rid2">2,3</a>]. However, later observational studies found no increase in bleeding [<a href="#rid6">6,7</a>]. (See  <a class="medical medical_review" href="/z/d/html/1585.html" rel="external">"Early noncardiac complications of coronary artery bypass graft surgery", section on 'Bleeding'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The issue of whether preoperative <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> decreases the risk of early vein graft occlusion was addressed in two Veterans Administration randomized trials. The first (1988) compared aspirin 325 mg daily, aspirin 325 mg three times daily, aspirin plus <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a> three times daily, sulfinpyrazone, and placebo. All therapy, except aspirin was started 48 hours before surgery and aspirin was given 12 hours before surgery. At 60 days, all regimens improved graft patency compared with placebo; however, the rate of reoperation after CABG was increased. The second trial (1991) compared the efficacy of aspirin (325 mg) or placebo given the night before surgery, with postoperative aspirin being given to all patients beginning six hours after surgery [<a href="#rid2">2</a>]. There was no difference in saphenous vein graft occlusion between the two groups at an average of eight days after surgery (7.4 versus 7.8 percent), but there was a nonsignificant trend toward a lower rate of occlusion of internal thoracic artery grafts (0 versus 2.4 percent) for the group receiving aspirin preoperatively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Observational data suggest that preoperative <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> may reduce in-hospital mortality [<a href="#rid6">6,7</a>]. This finding differs from that found in ATACAS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The benefits and risk of preoperative <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> were evaluated in a study of over 4143 patients undergoing CABG at the Cleveland Clinic, some of whom had aspirin discontinued six or more days before surgery and some within five days of surgery [<a href="#rid8">8</a>]. Among 1519 well-matched pairs of patients, there was no significant difference between those with early and late aspirin discontinuation with regard to the composite outcome of in-hospital mortality, myocardial infarction, and stroke (1.7 versus 1.8 percent). Use within five days was associated with a significantly greater rate of intraoperative transfusions (23 versus 20 percent), but a nonsignificant difference in the number of reoperations for bleeding (3.4 versus 2.4 percent).</p><p></p><p class="headingAnchor" id="H4"><span class="h3">Postoperative aspirin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> therapy in the early postoperative period appears to have significant mortality and morbidity benefits in patients who undergo CABG. This was suggested in an initial randomized trial in which 407 patients were assigned to either placebo or to <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a> (begun two days before surgery) plus aspirin (begun seven hours after surgery) [<a href="#rid9">9</a>]. Antiplatelet therapy significantly reduced the rate of graft occlusion at 30 days (6 versus 22 percent).</p><p>A benefit from postoperative <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> was also suggested in a prospective observational study of over 5000 patients who survived the first 48 hours after surgery [<a href="#rid10">10</a>]. Among patients treated with antiplatelet agents, such therapy was discontinued before surgery in 50 percent; after surgery, aspirin (at a dose of up to 650 mg) was given at the discretion of the physician.</p><p>The following benefits were noted in the 60 percent of patients who received <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> within 48 hours of revascularization (deaths or complications occurring before 48 hours were excluded from the analysis):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> was associated with significant reductions in subsequent in-hospital mortality (1.3 versus 4.0 percent), myocardial infarction (MI) (2.8 versus 5.4 percent), stroke (1.3 versus 2.6 percent), acute renal failure (0.9 versus 3.4 percent), and bowel infarction (0.3 versus 0.8 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The mortality benefit with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> was seen in all subgroups, but was much less (27 percent reduction) and not significant when aspirin was begun after 48 hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Small differences between the study groups could not account for the difference in outcomes. Furthermore, on multivariate analysis, no other factor or medication was independently associated with reduced rates of the above outcomes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There was no increase in the rate of bleeding, gastritis, infection, or impaired wound healing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The practices of giving platelet transfusions after reperfusion and of administering antifibrinolytic drugs (such as <a class="drug drug_general" data-topicid="8561" href="/z/d/drug information/8561.html" rel="external">aminocaproic acid</a>) to minimize postoperative bleeding were associated with <strong>increases</strong> in mortality and ischemic complications in both <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> users and nonusers; however, the outcomes were again better with aspirin therapy. The adverse effects of antifibrinolytic therapy in this report are in contrast to a number of other studies that have demonstrated no adverse effect on or a reduction in perioperative mortality. (See  <a class="medical medical_review" href="/z/d/html/1585.html" rel="external">"Early noncardiac complications of coronary artery bypass graft surgery", section on 'Bleeding'</a>.)</p><p></p><p class="headingAnchor" id="H416519115"><span class="h3">Aspirin summary</span><span class="headingEndMark"> — </span>In the past, concerns about bleeding risk led to the recommendation that <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> be discontinued three to five days before surgery in patients undergoing elective CABG. However, this general approach is no longer recommended. The 2015 American Heart Association Scientific Statement on “Secondary Prevention after Coronary Artery Bypass Graft Surgery” recommended that aspirin be started or continued preoperatively [<a href="#rid11">11</a>]. </p><p>In patients at increased risk of a cardiovascular thrombotic event, we typically continue <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> until the day of surgery. </p><p>Among stable patients not previously on <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, benefit may be seen with aspirin started one hour after surgery [<a href="#rid12">12,13</a>]. However, with increasing experience, some surgeons recommend continuation of aspirin throughout the preoperative period. As noted above, preoperative aspirin may be associated with a significant reduction in in-hospital mortality without a significant increase in bleeding [<a href="#rid6">6,7,14,15</a>]. Furthermore, cessation of aspirin before CABG may be associated with an increase in in-hospital mortality [<a href="#rid10">10</a>]. (See <a class="local">'Preoperative aspirin'</a> above.)</p><p>We suggest that, in patients already being treated, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> be continued perioperatively with the possible exception of those at very high risk for bleeding. Some of the deleterious effects of aspirin and other antiplatelet drugs on postoperative bleeding and transfusion requirements can be attenuated by antifibrinolytic therapy. (See  <a class="medical medical_review" href="/z/d/html/1585.html" rel="external">"Early noncardiac complications of coronary artery bypass graft surgery", section on 'Bleeding'</a>.)</p><p>We start or restart <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (with or without a loading dose) six hours after surgery or after extubation, whichever comes first. The decision of whether to give a loading dose (eg, 325 mg) of aspirin may be influenced by clinical factors such as recent acute coronary syndrome or concern about a risk of early graft failure. Low-dose aspirin should be continued indefinitely. With regard to timing and dose, bleeding risk needs to be considered.</p><p>Maintenance <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (usually 75 or 81 mg/day) is continued indefinitely for secondary prevention [<a href="#rid16">16</a>]. <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">Clopidogrel</a> (75 mg/day) is an alternative in patients with contraindications or allergies to aspirin. (See  <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">"Aspirin for the secondary prevention of atherosclerotic cardiovascular disease", section on 'Efficacy'</a> and  <a class="medical medical_review" href="/z/d/html/114687.html" rel="external">"Introduction of aspirin to patients with aspirin hypersensitivity requiring cardiovascular interventions"</a>.)</p><p><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> also prevents saphenous vein graft stenosis. (See  <a class="medical medical_review" href="/z/d/html/1565.html" rel="external">"Coronary artery bypass graft surgery: Prevention and management of vein graft stenosis", section on 'Antiplatelet agents'</a>.)</p><p>The benefits of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy and the adverse effect of platelet transfusion suggest that platelet activation plays an important role in the ischemic response to reperfusion injury [<a href="#rid12">12,17</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Platelet P2Y12 receptor blocker therapy</span></p><p class="headingAnchor" id="H1432472315"><span class="h3">Preoperative P2Y12 management</span><span class="headingEndMark"> — </span>For patients undergoing elective coronary artery bypass graft surgery (CABG) who are taking an oral platelet P2Y<sub>12</sub> receptor blocker (ie, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>, <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a>, <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a>), we discontinue it five to seven days before surgery. This practice is based on our clinical experience and observational study results. As examples: </p><p class="bulletIndent1"><span class="glyph">●</span>In a post-hoc analysis of a randomized trial that compared <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> with placebo in patients with non-ST-elevation MI, 93 percent of patients stopped the study medication prior to CABG surgery [<a href="#rid18">18</a>]. Patients who stopped clopidogrel &gt;5 days prior to surgery had a lower risk of life-threatening and major bleeding events (4.4 versus 9.6 percent in those stopping clopidogrel ≤5 days prior to surgery, relative risk [RR] 0.45, 95% CI 0.27-0.76).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a sub-study of another randomized trial that compared <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> with placebo in patients who received thrombolytics for ST-elevation MI, the study medication was stopped ≤5 days prior to CABG surgery in 54 percent of patients and was stopped &gt;5 days prior to surgery in the remainder of patients [<a href="#rid19">19</a>]. The group of patients stopping clopidogrel &gt;5 days prior to surgery had nonsignificantly lower rates of major and minor bleeding (6 versus 11 percent in the group stopping clopidogrel ≤5 days prior to surgery; RR 0.59, 95% CI 0.12-3.02). </p><p></p><p>We do not test for platelet reactivity in patients who recently took <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> and who are scheduled for urgent CABG, though the strategy of using platelet reactivity to delay surgery has been studied:</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective study of patients undergoing elective CABG, patients who were not taking <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> prior to surgery were compared to patients who recently discontinued clopidogrel [<a href="#rid20">20</a>]. In the group of patients who discontinued clopidogrel, surgery was scheduled (ie, surgery within one day, delayed three to five days, or delayed at least five days) according to the severity of platelet inhibition as measured by thromboelastography. The mean waiting period for CABG was 2.7 days from thromboelastography testing, which is shorter than the usual 5 to 7 day waiting period recommended after discontinuation of clopidogrel. The two groups did not have significant differences in chest tube drainage or the number of units of blood transfused.</p><p></p><p class="headingAnchor" id="H1497607036"><span class="h3">Postoperative P2Y12 management</span><span class="headingEndMark"> — </span>For patients who had CABG and have an ongoing indication for P2Y<sub>12</sub> inhibitor treatment (ie, recent acute coronary syndrome [ACS] or percutaneous coronary intervention in the last 12 months), some of our experts prescribe a P2Y<sub>12</sub> inhibitor after CABG and others do not. </p><p>Observational studies in patients with recent ACS and revascularization with CABG suggest that resuming P2Y<sub>12</sub> therapy as early as 10 to 30 days after CABG may result in a long-term clinical benefit. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a substudy from the CURE trial, 75 percent of patients who had CABG resumed <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> or placebo at a median of 10 days after CABG surgery [<a href="#rid18">18</a>]. One year after surgery, the group of patients assigned to clopidogrel had a nonsignificantly lower risk of CV death, MI, and stroke (relative risk compared to placebo 0.81, 95% CI 0.59-1.12). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A Danish registry study evaluated long-term outcomes in 945 patients who had CABG surgery within 180 days of a myocardial infarction and who claimed a prescription for <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> within 30 days after discharge from CABG surgery [<a href="#rid21">21</a>]. At a mean follow-up of 466 days after CABG surgery, patients who received clopidogrel had a lower risk of death or recurrent myocardial infarction than propensity-matched controls who did not receive clopidogrel (4.0 versus 6.0 percent in the control group; hazard ratio 0.67, 95% CI 0.44-1.00).</p><p></p><p>There is some evidence to suggest that <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> therapy for up to one year after off-pump CABG in stable patients, in addition to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, may decrease the rate of vein graft occlusion [<a href="#rid11">11,22,23</a>]. Some of our contributors prescribe clopidogrel in addition to aspirin for one year after off-pump surgery in stable patients while others do not. </p><p class="headingAnchor" id="H254331741"><span class="h2">Beta blockers</span><span class="headingEndMark"> — </span>In patients undergoing coronary artery bypass graft surgery (CABG), we start or continue beta blocker therapy prior to surgery to reduce the risk of atrial fibrillation. Further details on the use of beta blockers for prevention of atrial fibrillation can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1011.html" rel="external">"Atrial fibrillation and flutter after cardiac surgery", section on 'Prevention of atrial fibrillation and complications'</a>.)</p><p>Preoperative beta blocker therapy does not appear to reduce the risk of mortality in patients undergoing CABG. A 2014 review of patients who underwent CABG in the United States between 2008 and 2012 found no mortality benefit [<a href="#rid24">24</a>]. In this propensity-matched analysis of 138,542 individuals undergoing elective CABG, the rate of operative mortality between those who did and did not receive preoperative beta blockers within 24 hours of surgery was similar (1.1 versus 1.2 percent; odds ratio 0.96, 95% CI 0.87-1.06). The risk of permanent stroke was also similar (0.97 versus 0.98 percent; odds ratio 0.99, 95% CI 0.89-1.10). </p><p class="headingAnchor" id="H2034919252"><span class="h2">Statins</span><span class="headingEndMark"> — </span>There is a long-term mortality benefit from statin therapy in patients with coronary heart disease, including those who undergo coronary artery bypass graft surgery (CABG). Thus, most patients referred for CABG will be receiving a statin. (See  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a>.)</p><p>For patients who have not started statin therapy prior to CABG, the role of initiating statin therapy in the perioperative period to prevent atrial fibrillation is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1011.html" rel="external">"Atrial fibrillation and flutter after cardiac surgery"</a>.)</p><p class="headingAnchor" id="H112271285"><span class="h2">Angiotensin converting enzyme inhibitors</span><span class="headingEndMark"> — </span>The optimal use of angiotensin converting enzyme (ACE) inhibitors around the time of coronary artery bypass graft surgery (CABG) is not well established. Many patients undergoing CABG are taking long-term ACE inhibitors. We believe it is reasonable to continue ACE inhibitor after CABG in such patients who are hemodynamically stable.</p><p>It has been postulated that ACE inhibitors might improve outcomes at the time of CABG as the renin-angiotensin-aldosterone system is hyperactive during and after cardiopulmonary bypass (CPB). This hyperactivity is thought to be a mediator of microvascular injury and a trigger of endothelial dysfunction. (See  <a class="medical medical_review" href="/z/d/html/122165.html" rel="external">"Pharmacologic therapy of heart failure with reduced ejection fraction: Mechanisms of action", section on 'ACE inhibitors'</a>.)</p><p>Some studies of perioperative ACE inhibitor use have shown improved outcomes [<a href="#rid25">25,26</a>] while others have demonstrated worse outcomes [<a href="#rid27">27</a>]. Reports of intraoperative hypotension/vasoplegia in patients taking ACE inhibitors have led to the widespread practice of not performing elective surgery unless the medication had been held for a number of days [<a href="#rid28">28,29</a>].</p><p>The potential role of ACE inhibitor was addressed in a prospective, observational study of 4224 patients undergoing CABG with CPB [<a href="#rid30">30</a>]. In this study, four groups of patients were identified: ACE inhibitor before and after surgery (continuation), ACE inhibitor before but not after surgery (withdrawal), no ACE inhibitor at any time (never), and no ACE inhibitor before but ACE inhibitor after CABG (addition). The percent of patients in each group were 21.7, 21.8, 48.4, and 8.1, respectively. ACE inhibitor was generally held the day before CABG; the decision to start (and the timing of) therapy was at the discretion of the managing physician.</p><p>The following findings were noted for the primary composite outcome of in-hospital death, cardiovascular event (heart failure or myocardial infarction), cerebrovascular event, or renal event:</p><p class="bulletIndent1"><span class="glyph">●</span>The primary outcomes occurred in 12.8, 28.1, 14.1, and 11.6 percent of cases, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The adjusted odds ratio (OR) comparing the following pairs of groups were:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Continuation versus never: 0.69, 95% CI 0.52-0.91</p><p class="bulletIndent2"><span class="glyph">•</span>Continuation versus withdrawal: 0.50, 95% CI 0.38-0.66.</p><p class="bulletIndent2"><span class="glyph">•</span>Addition versus never: 0.56, 95% CI 0.38-0.84</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No differences in in-hospital mortality and cerebral events were seen.</p><p></p><p>We and others are concerned about the limitations of this observational study, including multiple potential sources of bias and the inability to extrapolate to other patient groups, such as those undergoing valve surgery or off-pump CABG [<a href="#rid31">31</a>]. Until further evidence is available to support the findings of this study, we believe it is reasonable to continue ACE inhibitor after CABG in hemodynamically stable patients taking this therapy before surgery. </p><p class="headingAnchor" id="H924382935"><span class="h1">OTHER THERAPIES TO PREVENTION ADVERSE OUTCOMES</span></p><p class="headingAnchor" id="H3539688559"><span class="h2">Glycemic control</span><span class="headingEndMark"> — </span>Most clinicians accept that prevention of uncontrolled hyperglycemia in critically ill patients, including those who have undergone coronary artery bypass graft surgery (CABG), is a desirable intervention. However, the optimal blood glucose range is controversial [<a href="#rid32">32</a>]. Numerous clinical trials have compared different ranges of blood glucose in various populations of critically ill patients, including patients who have undergone CABG. This issue is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1600.html" rel="external">"Glycemic control in critically ill adult and pediatric patients"</a>.)</p><p>The 2015 American Heart Association Scientific Statement on “Secondary Prevention after Coronary Artery Bypass Graft Surgery” recommended that striving to achieve an HBA<sub>1c </sub>of 7 percent is a reasonable goal for most patients after CABG [<a href="#rid33">33</a>]. </p><p class="headingAnchor" id="H14"><span class="h2">Glucocorticoid therapy</span><span class="headingEndMark"> — </span>Cardiopulmonary bypass initiates a systemic inflammatory response and glucocorticoid therapy is effective in lessening this response; thus, a potential role for routine preoperative glucocorticoid has been postulated [<a href="#rid34">34</a>]. Based on the totality of evidence presented below, including no improvement in mortality and a worsening in hyperglycemia, we do not recommend the routine preoperative use of glucocorticoids, except for patients who are receiving them chronically. </p><p>While early meta-analyses of small, randomized trials found a lower rate of postoperative atrial fibrillation (AF) with prophylactic glucocorticoid use, two subsequent large, randomized trials have not found a lower risk of AF or a lower risk of death [<a href="#rid34">34-36</a>]. (See  <a class="medical medical_review" href="/z/d/html/1011.html" rel="external">"Atrial fibrillation and flutter after cardiac surgery", section on 'Ineffective or possibly effective therapies'</a>.) The DECS trial randomly assigned 4494 cardiac surgery patients to a single, intraoperative dose of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> or placebo and found no significant difference in the risk of the composite end point of death, myocardial infarction, stroke, renal failure, or respiratory failure at 30 days [<a href="#rid37">37</a>]. The SIRS trial randomly assigned 7507 patients undergoing cardiac surgery to receive either high-dose <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> or placebo and found no difference in the risk of death (4 versus 5 percent, respectively) or a combined end point of death and major morbidity (24 percent in both groups) at 30 days [<a href="#rid38">38</a>].</p><p>Others have interpreted the data differently and made weak recommendations to use them in patients undergoing cardiopulmonary bypass surgery [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Antifibrinolytic agents</span><span class="headingEndMark"> — </span>In selected patients, antifibrinolytic agents such as <a class="drug drug_general" data-topicid="8561" href="/z/d/drug information/8561.html" rel="external">aminocaproic acid</a> and <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a> can reduce the amount of blood loss and the need for blood transfusions. The use of these drugs is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/94297.html" rel="external">"Blood management and anticoagulation for cardiopulmonary bypass", section on 'Antifibrinolytic administration'</a>.)</p><p class="headingAnchor" id="H192894665"><span class="h2">Antimicrobial prophylaxis</span><span class="headingEndMark"> — </span>The role of antimicrobial prophylaxis to prevent surgical site infection in patients undergoing CABG is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4043.html" rel="external">"Antimicrobial prophylaxis for prevention of surgical site infection in adults", section on 'Cardiac surgery'</a>.)</p><p class="headingAnchor" id="H166813756"><span class="h2">Dexmedetomidine</span><span class="headingEndMark"> — </span>There is some evidence to support the use of <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">dexmedetomidine</a> in patients undergoing cardiac surgery. The drug is a highly selective, centrally acting, alpha-2-agonist with anxiolytic, sedative, and analgesic effects. It is used for initial sedation of mechanically ventilated patients for up to 24 hours and has been used in transitioning cardiac surgical patients from the operating room to the intensive care unit. (See  <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">"Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects", section on 'Dexmedetomidine'</a>.)</p><p>Based on evidence suggesting that <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">clonidine</a>, another alpha-2 agonist, reduces the rate of some postoperative complications in cardiac surgical cases and that <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">dexmedetomidine</a> has a similar effect in noncardiac surgical cases [<a href="#rid40">40,41</a>], a single center observational study compared outcomes in 568 individuals undergoing cardiac surgery who received dexmedetomidine and 566 who did not [<a href="#rid42">42</a>]. After adjustment for differences between the groups, dexmedetomidine use reduced in-hospital (1.23 versus 4.59 percent; adjusted odds ratio [AOR] 0.34, 95% CI 0.192-0.614), 30-day (1.76 versus 4.12; AOR 0.39, 95% CI 0.226-0.665), and one-year (3.17 versus 7.95; AOR 0.47; 95% CI 0.312-0.701) mortality. The risk of cardiovascular complications was also significantly reduced. A second retrospective, observational study of 724 coronary artery bypass graft surgery patients made similar observations [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H3634492722"><span class="h1">THERAPIES TO PREVENT REPERFUSION INJURY</span></p><p class="headingAnchor" id="H223497369"><span class="h2">Pyridoxal 5'-phosphate monohydrate</span><span class="headingEndMark"> — </span>Pyridoxal 5'-phosphate monohydrate (MC-1), a naturally occurring metabolite of pyridoxine (vitamin B6), prevents cellular calcium overload after ischemia driven reperfusion injury [<a href="#rid44">44,45</a>]. Despite modest evidence for clinical benefit in a phase 2 trial, MC-1 did not reduce the composite end point of cardiovascular death or nonfatal myocardial infarction (MI) compared to placebo in the MEND-CABG II trial of over 3000 moderate to high risk coronary artery bypass graft surgery (CABG) patients undergoing cardiopulmonary bypass [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H2860154898"><span class="h2">Acadesine</span><span class="headingEndMark"> — </span>Intraoperative ischemia with reperfusion injury is an important cause of myocardial infarction, left ventricular systolic dysfunction, and death in patients undergoing coronary artery bypass graft surgery (CABG) or percutaneous coronary intervention. (See  <a class="medical medical_review" href="/z/d/html/1511.html" rel="external">"Reperfusion injury of the heart"</a>.)</p><p>Ischemic preconditioning is a potential therapy to reduce the severity of reperfusion injury and <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a> has been shown to be a facilitator of ischemic preconditioning. (See  <a class="medical medical_review" href="/z/d/html/1487.html" rel="external">"Myocardial ischemic conditioning: Pathogenesis", section on 'Ischemic preconditioning'</a> and  <a class="medical medical_review" href="/z/d/html/1487.html" rel="external">"Myocardial ischemic conditioning: Pathogenesis", section on 'Adenosine'</a>.)</p><p>While the administration of <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a> during CABG has not been shown to be beneficial, acadesine, an adenosine-regulating agent that increases intracellular levels of adenosine, reduced the rate of perioperative myocardial infarction (MI) and death in a 1997 meta-analysis of five relatively small randomized trials [<a href="#rid47">47</a>]. However, since the late 1990s, perioperative mortality and non-fatal cardiovascular events have fallen by up to 40 percent, probably attributable to improvements in perioperative management and in myocardial protection techniques. Thus, we feel that the findings in this meta-analysis may not apply to patients cared for more recently.</p><p>The RED-CABG trial, which randomly assigned intermediate- to high-risk patients undergoing nonemergency CABG to either perioperative acadesine or placebo, was designed to better evaluate the efficacy of acadesine [<a href="#rid48">48</a>]. The trial was stopped after enrollment of 3080 of the originally projected 7500 patients, as the results of a prespecified futility analysis found no difference in the rate (approximately 5 percent in both groups) of the primary composite outcome of all-cause mortality, nonfatal stroke, or need for mechanical support for severe left ventricular dysfunction.</p><p class="headingAnchor" id="H113908941"><span class="h1">CARDIAC REHABILITATION</span><span class="headingEndMark"> — </span>The 2015 American Heart Association Scientific Statement on “Secondary Prevention after Coronary Artery Bypass Graft Surgery” recommended referral to a cardiac rehabilitation program for all patients [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/1552.html" rel="external">"Cardiac rehabilitation: Indications, efficacy, and safety in patients with coronary heart disease", section on 'Indications'</a>.)</p><p class="headingAnchor" id="H2641141327"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119298.html" rel="external">"Society guideline links: Coronary artery bypass graft surgery"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/3425.html" rel="external">"Patient education: Coronary artery bypass graft surgery (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/3432.html" rel="external">"Patient education: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)"</a>) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/16430.html" rel="external">"Patient education: Coronary artery bypass graft surgery (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2604450"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a><strong> </strong>–<strong> </strong>All patients with cardiovascular disease (CVD) require life-long aspirin to prevent ischemic cardiovascular events as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">"Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent1">For most patients already taking <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, we suggest continuing aspirin up to the day of coronary artery bypass graft surgery (CABG) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Preoperative aspirin'</a> above.) </p><p></p><p class="bulletIndent1">After CABG, we initiate or resume <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy. We suggest starting aspirin six hours after surgery or after extubation, whichever comes first (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Aspirin'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>P2Y12 inhibitors </strong>–<strong> </strong>In patients who are taking a P2Y12 inhibitor (eg, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>, <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a>) and are scheduled for CABG, we suggest discontinuing the P2Y12 inhibitor ≥5 days prior to surgery (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Preoperative P2Y12 management'</a> above.) </p><p></p><p class="bulletIndent1">The benefit of long-term P2Y12 inhibitor therapy after CABG is unclear. Some of our contributors resume a P2Y12 inhibitor after CABG, while others do not. (See <a class="local">'Postoperative P2Y12 management'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta blockers </strong>– Beta blockers in the perioperative period have been shown to prevent atrial fibrillation and are routinely used after CABG, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1011.html" rel="external">"Atrial fibrillation and flutter after cardiac surgery", section on 'Prevention of atrial fibrillation and complications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Statins</strong> – There is a long-term mortality benefit from statin therapy in patients with coronary heart disease, including those who undergo CABG. Thus, most patients referred for CABG will be receiving a statin, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a>.) </p><p></p><p class="bulletIndent1">For patients who have not started statin therapy prior to CABG, the role of initiating statin therapy in the perioperative period to prevent atrial fibrillation is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1011.html" rel="external">"Atrial fibrillation and flutter after cardiac surgery"</a>.)</p><p></p><p class="headingAnchor" id="H3239660930"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff would like to thank Dr. Julian M. Aroesty for his contributions as an author to prior versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Collaborative overview of randomised trials of antiplatelet therapy--II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. BMJ 1994; 308:159.</a></li><li><a class="nounderline abstract_t">Goldman S, Copeland J, Moritz T, et al. Starting aspirin therapy after operation. Effects on early graft patency. Department of Veterans Affairs Cooperative Study Group. Circulation 1991; 84:520.</a></li><li><a class="nounderline abstract_t">Sethi GK, Copeland JG, Goldman S, et al. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy. J Am Coll Cardiol 1990; 15:15.</a></li><li><a class="nounderline abstract_t">Myles PS, Smith JA, Forbes A, et al. Stopping vs. Continuing Aspirin before Coronary Artery Surgery. N Engl J Med 2016; 374:728.</a></li><li><a class="nounderline abstract_t">Myles PS, Smith JA, Kasza J, et al. Aspirin in coronary artery surgery: 1-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial. J Thorac Cardiovasc Surg 2019; 157:633.</a></li><li><a class="nounderline abstract_t">Bybee KA, Powell BD, Valeti U, et al. Preoperative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting. Circulation 2005; 112:I286.</a></li><li><a class="nounderline abstract_t">Dacey LJ, Munoz JJ, Johnson ER, et al. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. Ann Thorac Surg 2000; 70:1986.</a></li><li><a class="nounderline abstract_t">Jacob M, Smedira N, Blackstone E, et al. Effect of timing of chronic preoperative aspirin discontinuation on morbidity and mortality in coronary artery bypass surgery. Circulation 2011; 123:577.</a></li><li><a class="nounderline abstract_t">Fuster V, Chesebro JH. Role of platelets and platelet inhibitors in aortocoronary artery vein-graft disease. Circulation 1986; 73:227.</a></li><li><a class="nounderline abstract_t">Mangano DT, Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002; 347:1309.</a></li><li><a class="nounderline abstract_t">Kulik A, Ruel M, Jneid H, et al. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. Circulation 2015; 131:927.</a></li><li><a class="nounderline abstract_t">Topol EJ. Aspirin with bypass surgery--from taboo to new standard of care. N Engl J Med 2002; 347:1359.</a></li><li><a class="nounderline abstract_t">Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. Circulation 1991; 83:1526.</a></li><li><a class="nounderline abstract_t">Sun JC, Crowther MA, Warkentin TE, et al. Should aspirin be discontinued before coronary artery bypass surgery? Circulation 2005; 112:e85.</a></li><li><a class="nounderline abstract_t">Cannon CP, Mehta SR, Aranki SF. Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery. Ann Thorac Surg 2005; 80:768.</a></li><li><a class="nounderline abstract_t">Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71.</a></li><li><a class="nounderline abstract_t">Henn V, Slupsky JR, Gräfe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391:591.</a></li><li><a class="nounderline abstract_t">Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004; 110:1202.</a></li><li><a class="nounderline abstract_t">McLean DS, Sabatine MS, Guo W, et al. Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. J Thromb Thrombolysis 2007; 24:85.</a></li><li><a class="nounderline abstract_t">Mahla E, Suarez TA, Bliden KP, et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv 2012; 5:261.</a></li><li><a class="nounderline abstract_t">Sørensen R, Abildstrøm SZ, Hansen PR, et al. Efficacy of post-operative clopidogrel treatment in patients revascularized with coronary artery bypass grafting after myocardial infarction. J Am Coll Cardiol 2011; 57:1202.</a></li><li><a class="nounderline abstract_t">Deo SV, Dunlay SM, Shah IK, et al. Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis. J Card Surg 2013; 28:109.</a></li><li><a class="nounderline abstract_t">Mannacio VA, Di Tommaso L, Antignan A, et al. Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study. Heart 2012; 98:1710.</a></li><li><a class="nounderline abstract_t">Brinkman W, Herbert MA, O'Brien S, et al. Preoperative β-blocker use in coronary artery bypass grafting surgery: national database analysis. JAMA Intern Med 2014; 174:1320.</a></li><li><a class="nounderline abstract_t">Oosterga M, Voors AA, Pinto YM, et al. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on Vascular Ace and Determinants of Ischemia. Am J Cardiol 2001; 87:542.</a></li><li><a class="nounderline abstract_t">Kjøller-Hansen L, Steffensen R, Grande P. The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). J Am Coll Cardiol 2000; 35:881.</a></li><li><a class="nounderline abstract_t">Miceli A, Capoun R, Fino C, et al. Effects of angiotensin-converting enzyme inhibitor therapy on clinical outcome in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 2009; 54:1778.</a></li><li><a class="nounderline abstract_t">Tuman KJ, McCarthy RJ, O'Connor CJ, et al. Angiotensin-converting enzyme inhibitors increase vasoconstrictor requirements after cardiopulmonary bypass. Anesth Analg 1995; 80:473.</a></li><li><a class="nounderline abstract_t">Oh YJ, Lee JH, Nam SB, et al. Effects of chronic angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor treatments on neurohormonal levels and haemodynamics during cardiopulmonary bypass. Br J Anaesth 2006; 97:792.</a></li><li><a class="nounderline abstract_t">Drenger B, Fontes ML, Miao Y, et al. Patterns of use of perioperative angiotensin-converting enzyme inhibitors in coronary artery bypass graft surgery with cardiopulmonary bypass: effects on in-hospital morbidity and mortality. Circulation 2012; 126:261.</a></li><li><a class="nounderline abstract_t">Barodka V, Nyhan D, Berkowitz D. About fACE: perioperative use of angiotensin-converting enzyme inhibitors. Circulation 2012; 126:249.</a></li><li><a class="nounderline abstract_t">Qaseem A, Humphrey LL, Chou R, et al. Use of intensive insulin therapy for the management of glycemic control in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2011; 154:260.</a></li><li><a class="nounderline abstract_t">Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:2610.</a></li><li><a class="nounderline abstract_t">Whitlock RP, Chan S, Devereaux PJ, et al. Clinical benefit of steroid use in patients undergoing cardiopulmonary bypass: a meta-analysis of randomized trials. Eur Heart J 2008; 29:2592.</a></li><li><a class="nounderline abstract_t">Ho KM, Tan JA. Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose-response meta-analysis. Circulation 2009; 119:1853.</a></li><li><a class="nounderline abstract_t">Dieleman JM, van Paassen J, van Dijk D, et al. Prophylactic corticosteroids for cardiopulmonary bypass in adults. Cochrane Database Syst Rev 2011; :CD005566.</a></li><li><a class="nounderline abstract_t">Dieleman JM, Nierich AP, Rosseel PM, et al. Intraoperative high-dose dexamethasone for cardiac surgery: a randomized controlled trial. JAMA 2012; 308:1761.</a></li><li><a class="nounderline abstract_t">Whitlock RP, Devereaux PJ, Teoh KH, et al. Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 386:1243.</a></li><li><a class="nounderline abstract_t">Pastores SM, Annane D, Rochwerg B, Corticosteroid Guideline Task Force of SCCM and ESICM. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part II): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Med 2018; 44:474.</a></li><li><a class="nounderline abstract_t">Nishina K, Mikawa K, Uesugi T, et al. Efficacy of clonidine for prevention of perioperative myocardial ischemia: a critical appraisal and meta-analysis of the literature. Anesthesiology 2002; 96:323.</a></li><li><a class="nounderline abstract_t">Wijeysundera DN, Naik JS, Beattie WS. Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. Am J Med 2003; 114:742.</a></li><li><a class="nounderline abstract_t">Ji F, Li Z, Nguyen H, et al. Perioperative dexmedetomidine improves outcomes of cardiac surgery. Circulation 2013; 127:1576.</a></li><li><a class="nounderline abstract_t">Ji F, Li Z, Young N, et al. Perioperative dexmedetomidine improves mortality in patients undergoing coronary artery bypass surgery. J Cardiothorac Vasc Anesth 2014; 28:267.</a></li><li><a class="nounderline abstract_t">Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357:1121.</a></li><li><a class="nounderline abstract_t">Tardif JC, Carrier M, Kandzari DE, et al. Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study. J Thorac Cardiovasc Surg 2007; 133:1604.</a></li><li><a class="nounderline abstract_t">MEND-CABG II Investigators, Alexander JH, Emery RW Jr, et al. Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial. JAMA 2008; 299:1777.</a></li><li><a class="nounderline abstract_t">Mangano DT. Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group. JAMA 1997; 277:325.</a></li><li><a class="nounderline abstract_t">Newman MF, Ferguson TB, White JA, et al. Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial. JAMA 2012; 308:157.</a></li></ol></div><div id="topicVersionRevision">Topic 1556 Version 52.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8312766" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Collaborative overview of randomised trials of antiplatelet therapy--II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1860197" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Starting aspirin therapy after operation. Effects on early graft patency. Department of Veterans Affairs Cooperative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2404046" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26933848" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Stopping vs. Continuing Aspirin before Coronary Artery Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30401528" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Aspirin in coronary artery surgery: 1-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16159833" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Preoperative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11156107" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21282503" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effect of timing of chronic preoperative aspirin discontinuation on morbidity and mortality in coronary artery bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3510762" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Role of platelets and platelet inhibitors in aortocoronary artery vein-graft disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12397188" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Aspirin and mortality from coronary bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25679302" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12397195" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Aspirin with bypass surgery--from taboo to new standard of care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2022014" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16103244" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Should aspirin be discontinued before coronary artery bypass surgery?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16039260" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11786451" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9468137" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15313956" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17323134" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22396581" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21371637" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Efficacy of post-operative clopidogrel treatment in patients revascularized with coronary artery bypass grafting after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23488578" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22942294" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24934977" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Preoperativeβ-blocker use in coronary artery bypass grafting surgery: national database analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11230836" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on Vascular Ace and Determinants of Ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10732883" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19682819" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effects of angiotensin-converting enzyme inhibitor therapy on clinical outcome in patients undergoing coronary artery bypass grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7864410" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Angiotensin-converting enzyme inhibitors increase vasoconstrictor requirements after cardiopulmonary bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17032660" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effects of chronic angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor treatments on neurohormonal levels and haemodynamics during cardiopulmonary bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22715473" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Patterns of use of perioperative angiotensin-converting enzyme inhibitors in coronary artery bypass graft surgery with cardiopulmonary bypass: effects on in-hospital morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22715474" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : About fACE: perioperative use of angiotensin-converting enzyme inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21320941" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Use of intensive insulin therapy for the management of glycemic control in hospitalized patients: a clinical practice guideline from the American College of Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22064600" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18664462" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clinical benefit of steroid use in patients undergoing cardiopulmonary bypass: a meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19332460" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose-response meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21563145" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Prophylactic corticosteroids for cardiopulmonary bypass in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23117776" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Intraoperative high-dose dexamethasone for cardiac surgery: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26460660" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29090327" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part II): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11818763" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Efficacy of clonidine for prevention of perioperative myocardial ischemia: a critical appraisal and meta-analysis of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12829201" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23513068" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Perioperative dexmedetomidine improves outcomes of cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24182835" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Perioperative dexmedetomidine improves mortality in patients undergoing coronary artery bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17855673" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Myocardial reperfusion injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17532963" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18381567" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9002496" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22782417" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
